Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 878 participants.
Also called NCT03798054
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 878 participants
- Sponsor
- Registry
-
NCT03798054
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, Malaysia, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03798054. Randomized; no masking; primary purpose treatment. Start 2019-02-15 (actual); primary completion 2021-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- Acronym
- Lixilan-O-AP
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide (HOE901/AVE0010)
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03798054- Content hash
96b17a7b3530e8ace7b5948fc8259770402cb8465d1e94e73ba2f7932aca1774